Clinical Study Results

What treatments did the participants take?

The participants in this study took midazolam and savolitinib.

The participants took midazolam as a liquid by mouth, and savolitinib as a pill by mouth.

This was an "open-label" study. This means the participants, researchers, study doctors, and other study staff knew what each participant was taking.

Study treatment happened in 2 parts. The same participants were in both parts. The chart below shows the treatments the participants took.

First part of treatment Second part of treatment
(14 participants) (14 participants)
What study treatment 
did the participants take? 

- All of the participants took midazolam as a liquid by mouth
- All of the participants took savolitinib as a pill by mouth

How often did the 
participants take study 
treatment?

- 1 time
- Midazolam 1 time
- Savolitinib 1 time

What happened during the study?

The study started in December 2019 and ended in March 2020.

Before the participants took treatment, they visited their study site 1 time over the course of about 1 month. During this visit, the study doctors checked to make sure the participants could join the study. The study doctors:
- Did a physical examination
- Took blood and urine samples
- Checked the participants' heart health using an electrocardiogram, also called an ECG
- Asked the participants about their medical history, how they were feeling, and what medicines they were taking